The management of patients with metastatic non-small cell lung cancer (NSCLC) is a field which has seen drastic improvement in the past few years. Here, Alastair Greystoke, PhD, of the University of Newcastle & Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, illustrates this through the dramatic number of changes in treatment algorithms six times within the last 3 years in the UK. He attributes this to the introduction of readily available immunotherapies on the NHS, including pembrolizumab, nivolumab and atezolizumab. This video was recorded at the UK Oncology Forum (OF) 2018, held in Liverpool, UK.
Progress in novel NSCLC therapies in the UK
